Literature DB >> 35946532

Healthcare policy for COVID-19 patients on haemodialysis: Adapting to the changing needs of the Omicron variant.

Deanna Xiuting Koh1, James Jianhong Chen2, Martin Yong Kwong Lee1, Chieh Suai Tan3, Elizabeth Wan Ling Tan1, Si Jack Chong1, Yock Young Dan4.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 35946532      PMCID: PMC9538061          DOI: 10.1111/nep.14082

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.358


× No keyword cloud information.
Singapore's COVID‐19 healthcare policies strive for resource‐efficient ways to ensure safety of the community and individual patient groups‐ including the 7500 people here on Haemodialysis (HD). These have higher COVID‐19 infection and mortality risk than the general population and operationally‐demanding healthcare needs. Delta (dominant October 2021) was a COVID‐19 variant of concern due to its 60% greater hospitalization rate and higher mortality compared to its predecessors. The policy then was therefore hospital‐based recovery for all HD patients. Omicron then overtook Delta as the dominant strain in January 2022‐ its lower virulence allowing safe management of HD patients in lower acuity COVID‐19 Treatment Facilities (CTFs) providing 24‐h medical care and COVID‐19 therapeutics, instead. These patients would undergo dialysis at 2 designated National Dialysis Centres (NDCs). Pre‐pandemically, the NDCs could serve 40 patients daily, but the policy to dialyse all COVID‐19 HD patients at NDCs during Omicron resulted in excess demand despite tripling their capacity. The missed HD sessions increased hospitalization rate among COVID‐19 HD patients from 8 February to 21 February 2022 (Figure 1).
FIGURE 1

The number of COVID‐19‐infected HD patients increased throughout January and February 2022, along with that of the general population. Admitting HD patients into the Ministry of Health's Home Recovery Programme (HRP) reduced demand on CTF beds and NDC dialysis slots. The safety of HRP for HD patients is evidenced by the decline hospital escalations

The number of COVID‐19‐infected HD patients increased throughout January and February 2022, along with that of the general population. Admitting HD patients into the Ministry of Health's Home Recovery Programme (HRP) reduced demand on CTF beds and NDC dialysis slots. The safety of HRP for HD patients is evidenced by the decline hospital escalations Evidence of Omicron's milder disease, however, allowed for a policy change on 21 February 2022‐where clinically‐well HD patients without immunocompromising co‐morbidities recover at home while receiving HD at their original Regional Dialysis Centre (RDC) under a Home Recovery Programme (HRP). HRP is part of the larger COVID‐19 care model in Singapore, where a national triaging system determines if patients recover in hospital, a CTF, or at home with Telemedical support (HRP). Decentralization of care to RDCs saved 367 CTF beds, 1431 CTF bed‐days and 645 NDC dialysis slots. HRP also allowed patients to recover under the support of familiar RDC staff and avoided logistical issues. After 21 February 2022, only HD patients unsuitable for HRP (i.e., unable to isolate from high‐risk residents within the same home), were admitted to CTFs. One concern was infection control, since RDCs provide HD to both COVID‐19 and non‐COVID‐19 patients. Cohorting COVID‐19 HD patients and allocating them the last HD session for the day followed by full decontamination helped achieve zero RDC COVID‐19‐infection clusters. This policy allowing HD patients without immunocompromising comorbidities home recovery and dialysis at their RDC saved resources and was safe for them and community, in the context of an Omicron‐like (lower virulence, higher infectivity) variant and highly vaccinated population.
  3 in total

1.  COVID-19 in patients undergoing long-term dialysis in Ontario.

Authors:  Leena Taji; Doneal Thomas; Matthew J Oliver; Jane Ip; Yiwen Tang; Angie Yeung; Rebecca Cooper; Andrew A House; Phil McFarlane; Peter G Blake
Journal:  CMAJ       Date:  2021-02-04       Impact factor: 8.262

Review 2.  Delta Variant: The New Challenge of COVID-19 Pandemic, an Overview of Epidemiological, Clinical, and Immune Characteristics.

Authors:  Noosha Samieefar; Ronak Rashedi; Meisam Akhlaghdoust; Melika Mashhadi; Pouya Darzi; Nima Rezaei
Journal:  Acta Biomed       Date:  2022-03-14

3.  COVID-19 severity from Omicron and Delta SARS-CoV-2 variants.

Authors:  Jesse O Wrenn; Suman B Pakala; Grant Vestal; Meghan H Shilts; Hunter M Brown; Sara M Bowen; Britton A Strickland; Timothy Williams; Simon A Mallal; Ian D Jones; Jonathan E Schmitz; Wesley H Self; Suman R Das
Journal:  Influenza Other Respir Viruses       Date:  2022-04-13       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.